Molecular Dynamics MegaBACE 1000 DNA sequencer sales ramp-up depends on initial market acceptance.
This article was originally published in The Gray Sheet
MOLECULAR DYNAMICS MEGABACE 1000 DNA SEQUENCER FULL-SCALE LAUNCH is contingent on the level of market acceptance in the second phase of the company's three-stage roll-out strategy, the company says. "During the latter part of 1998, we will go into the broader market launch of this product, but that will depend on the level of demand we experience in" the ongoing phase-two marketing, President and CEO Jay Flatley told investors at a Jan. 12 session of the Hambrecht & Quist health care conference in San Francisco.
You may also be interested in...
Lannett will launch a further seven products in fiscal 2021, after launching four products recently in the first quarter of FY21. The company also plans to pay off its Term Loan ‘A’ in full, by the end of November 2020.
Pfizer has now received a formal European Commission approval for its Nyvepria biosimilar pegfilgrastim. The approval puts the firm in direct competition with several other versions of the Neulasta original.
AstraZeneca's research head admits that the half dose approach was a lucky mistake – but one that could boost the vaccine's effectiveness and supplies. The US regulator may not be persuaded, however.